A healthy US agricultural sector is critical to global food security. American farmers help keep food affordable around the world, but they also receive public assistance that too often comes at the expense of American taxpayers and consumers, as well as millions of poor farmers in developing countries. While the farm bill is not the primary vehicle for setting policy on biofuels or antibiotic use, Congress could use the legislation to advance smart policy changes that set the stage for broader reforms.
In Global Agriculture and the American Farmer, Kimberly Elliott focuses on three policy areas that are particularly damaging for developing countries: traditional agricultural subsidy and trade policies that support the incomes of American farmers at the expense of farmers elsewhere; the biofuels mandate, which in its current form can contribute to market volatility while doing little if anything to mitigate climate change; and weak regulation of antibiotic use in livestock, which contributes to the global spread of drug-resistant super bugs. While noting that broad reforms are needed to fix these problems, Elliott also identifies practical steps that US policymakers could take in the relatively short run to improve farm policies—for American taxpayers and consumers as well as for the poor and vulnerable in developing countries.
While the misuse of antimicrobials in human health is a key factor accelerating the emergence of drug resistance, we should not overlook the role of agriculture. This paper makes the case for a global treaty to reduce antimicrobial use in livestock.
The discovery of antibiotics in the early 20th Century was a major breakthrough for human health, markedly reducing the infection threat from minor cuts, surgery, and cancer treatment.
The US has an untapped opportunity to offer global leadership against drug resistance through the major global health programs it already supports, namely PEPFAR, the Global Fund, and the Presidents Malaria Imitative. In this memo, Victoria Fan and Amanda Glassman highlight considerations for Congress with respect to oversight of these key channels of US development assistance for health that greatly affect drug resistance.
The Center for Global Development’s Drug Resistance Working Group urges pharmaceutical companies, governments, donors, global health institutions, health providers, and patients to collectively and immediately tackle this global health threat by implementing four key recommendations.
In an increasingly interconnected world, drug resistance does not stop at a patient’s bedside—it threatens global health. The conclusions of the Center for Global Development’s Drug Resistance Working Group make clear the need for urgent action to address this growing crisis.
Countering Drug Resistance in the Developing World: An Assessment of Incentives across the Value Chain and Recommendations for Policy Interventions - Working Paper 183
In this working paper, commissioned as part of CGD's Drug Resistance Working Group, Prashant Yadav analyzes how changes in supply-chain business practices could help fix the misaligned incentives that hinder worldwide access to high-quality medical goods.
CGD policy analyst Lindsay Morgan summarizes the global health agendas various organizations have recommended to the Obama administration. She finds that the calls for a smarter, more harmonized, results-based global health agenda are clear.